Get the Stockscreener App
8.22
2.37%
0.19
After Hours:
8.22
Arvinas Inc stock is traded at $8.22, with a volume of 475.55K.
It is up +2.37% in the last 24 hours and up +2.75% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$8.03
Open:
$8.13
24h Volume:
475.55K
Relative Volume:
0.60
Market Cap:
$530.36M
Revenue:
$89.40M
Net Income/Loss:
$-221.30M
P/E Ratio:
-2.5243
EPS:
-3.2564
Net Cash Flow:
$-256.90M
1W Performance:
+2.49%
1M Performance:
+2.75%
6M Performance:
-39.65%
1Y Performance:
+4.85%
1-Day Range:
$8.12
$8.37
1-Week Range:
$7.95
$8.40
52-Week Range:
$6.055
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
8.22 | 518.11M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Arvinas Inc (ARVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arvinas, Inc. $ARVN is Rangeley Capital LLC's 8th Largest Position - MarketBeat
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Arvinas Inc (ARVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arvinas (NASDAQ:ARVN) Upgraded at Wall Street Zen - MarketBeat
TradingKey - TradingKey
Caxton Associates LLP Decreases Stake in Arvinas, Inc. $ARVN - MarketBeat
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Arvinas, Inc. Revenue Breakdown – NASDAQ:ARVN - TradingView
Arvinas Inc (ARVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arvinas (ARVN) AGM 2026 Summary - Quartr
Arvinas (ARVN) Proxy filing Summary - Quartr
Trading the Move, Not the Narrative: (ARVN) Edition - Stock Traders Daily
Arvinas (ARVN) Stock Forum and Discussion - Moomoo
ARVN News | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Protein Degrader Therapeutics (PROTACs & Molecular Glues) - openPR.com
Form 144 ARVINAS For: 9 July By Investing.com - Investing.com Nigeria
Morgan Stanley (ARVN) broker files Form 144 to sell 24,000 shares - Stock Titan
ARVN Q1 2026 Earnings: EPS Beat Amidst No Revenue, Pipeline Progress in FocusGross Profit Margin - DonanımHaber
Why FDA approval for vepdegestrant is a major shift in cancer therapy - The Hindu
Arvinas Inc. (ARVN) Q1 2026 Earnings: Narrower Loss Surpasses ExpectationsRevenue Recognition Risk - dars.gov.et
ARVNArvinas Inc Latest SEC Filings - Finviz
Arvinas Inc. (ARVN) Narrows to a Fractional Decline, Stabilizing Near $8.29 Amid Low VolatilitySector Neutral Pair - dars.gov.et
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Form 4 Arvinas Inc For: 26 June By Investing.com - Investing.com South Africa
Arvinas (NASDAQ: ARVN) director receives RSU and option grants in new Form 4 - Stock Titan
Arvinas (ARVN) director receives RSU and stock option grants in equity award - Stock Titan
Arvinas (ARVN) director Briggs Morrison granted RSUs and stock options - Stock Titan
[Form 4] ARVINAS, INC. Insider Trading Activity - Stock Titan
Arvinas (ARVN) director receives new RSU and stock option awards - Stock Titan
Director Linda Bain receives RSUs and stock options at Arvinas (ARVN) - Stock Titan
Arvinas Inc (ARVN) Institutional Confidence - TradingKey
Arvinas, Inc. (NASDAQ: ARVN) Files Form 8-K: Key Company Details, Stock Info, and Compliance Disclosures (June 24, 2026) – Minichart - Minichart
Arvinas Inc (ARVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arvinas, Inc. Actuals & Estimates (NASDAQ:ARVN) - TradingView
Arvinas Shareholders Back Directors, Pay and Auditor Choices - TipRanks
Arvinas (NASDAQ: ARVN) investors back directors, pay and auditor - Stock Titan
ARVN Forecast — Price Target — Prediction for 2027 - TradingView
Arvinas CFO Andrew Saik sells $46,473 in company stock - Investing.com UK
Form 4 Arvinas Inc For: 24 June By Investing.com - Investing.com Nigeria
Arvinas CFO Andrew Saik sells $46,473 in company stock By Investing.com - Investing.com Australia
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):